Clinical Trials Logo

Conjunctivitis, Vernal clinical trials

View clinical trials related to Conjunctivitis, Vernal.

Filter by:
  • None
  • Page 1

NCT ID: NCT05038241 Completed - Clinical trials for Conjunctivitis, Vernal

HORMONES IN VERNAL KERATOCONJUNCTIVITIS

HOR-VKC-2020
Start date: April 1, 2021
Phase:
Study type: Observational

VKC is more common in males and tends to resolve with pubertal development. Clinical observation was not followed by an investigation that clarified whether there is a correlation between the hormonal pattern and the evolution of the disease, in particular it is not defined whether there is a correlation between the hormonal pattern and the resolution of the disease. This study aims to evaluate the hormonal pattern in patients with VKC and, in particular, the possible role of these hormones in the resolution of this condition in puberty.

NCT ID: NCT03186755 Recruiting - Clinical trials for Conjunctivitis, Allergic

Clinical Evaluation of Hylo-Dual Versus Patanol in Children With Seasonal Allergic Conjunctivitis

Start date: June 11, 2017
Phase: Phase 4
Study type: Interventional

This study compares the efficacy of Hylo-Dual (Hyaluronic acid 0.05% & Ectoine 2.0%) and Olopatadine (Olopatadine hydrochloride ophthalmic solution 0.1%) in the control of seasonal allergic conjunctivitis in the pediatric population. Half of participants will receive Hylo-Dual, while the other half will receive Olopatadine treatment for 2 months.

NCT ID: NCT00328653 Completed - Clinical trials for Conjunctivitis, Vernal

Efficacy and Tolerance of Nova22007 Versus Vehicle in Patients With Vernal Keratoconjunctivitis (VKC)

Start date: May 2006
Phase: Phase 2/Phase 3
Study type: Interventional

The primary objective of this study is: - To assess the efficacy of Nova22007, a cyclosporine A (CsA), 0.05% and 0.1% versus vehicle in patients with vernal keratoconjunctivitis (VKC) after a 4-week treatment period. The secondary objectives of this study are: - To compare the safety and ocular tolerance of Nova22007 0.05% and 0.1%; - To assess the long term safety and ocular tolerance of Nova22007 0.05% and 0.1%; and - To assess the decrease in frequency of concomitant artificial tears use.